Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07454668 · ClinicalTrials.gov registry record · Phase 1
Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases
A Phase 1 study, sponsored by Baptist Health South Florida.
- Not yet
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT07454668 is a Phase 1 study that has not yet begun recruiting, run by Baptist Health South Florida. The registered enrollment target is 20 participants.
The verdict
NCT07454668, a Phase 1 study, has not yet begun recruiting, sponsored by Baptist Health South Florida.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
A phase I clinical trial (a type of research study) for people with human epidermal growth factor receptor 2 (HER-2) positive breast cancer with metastasis to the brain. This research study will evaluate how well brain metastases can be controlled using a type of radiation therapy known as stereotactic radiosurgery (SRS) when combined with the therapeutic agent Trastuzumab Deruxtecan (T-DXd). The combined use of SRS with T-DXd is considered investigational.
Interventions
- RADIATION Stereotactic Radiosurgery
- DRUG Trastuzumab Deruxtecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-06 |
| Est. Completion | 2029-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07454668
The ClinicalTrials.gov registry entry for NCT07454668 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baptist Health South Florida, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Stereotactic Radiosurgery is the first listed.
NCT07454668 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07454668 about?
NCT07454668 is a clinical study titled "Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases". A phase I clinical trial (a type of research study) for people with human epidermal growth factor receptor 2 (HER-2) positive breast cancer with metastasis to the brain. This research study will evaluate how well brain metastases can be controlled using a type of radiation therapy known as stereotac...
What is the current status of trial NCT07454668?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2026-06. Estimated completion is 2029-07.
What interventions are being tested in trial NCT07454668?
The interventions under investigation include: Stereotactic Radiosurgery (RADIATION), Trastuzumab Deruxtecan (DRUG).
Who is sponsoring clinical trial NCT07454668?
This trial is sponsored by Baptist Health South Florida, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.